Use of Daratumumab, a CD38 monoclonal antibody, in advanced multiple myeloma

Share :
Published: 18 Jun 2013
Views: 4985
Prof Heinrich Lokhorst - Universitair Medisch Centrum Utrecht, Heidelberglaan, Netherlands

Dr Henk Lokhorst presented the results from a phase I/II study in advanced Multiple Myeloma at the 18th EHA meeting.

Multiple myeloma is the second most common haematological cancer. It is a cancer of the plasma cells and it accounts for approx. 1% of all cancers. At present, no cure is available. The 5-year relative survival rate for multiple myeloma is around 40% so there is a strong need for new treatment modalities to improve the survival.

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.


Visit ecancerNews to read more